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Monoclonal antibodies (mAb) have been shown effective in inducing immune tolerance
in a range of animal models of autoimmunity, allergy, and transplantation. We investi-
gated whether CD4-blockade, effective in inducing transplantation tolerance, could prevent
systemic immune responses leading to anaphylaxis. We found that treatment with a non-
depleting anti-CD4 mAb could prevent peanut-induced anaphylaxis following subsequent
systemic exposure to crude peanut extract (CPE). Furthermore, the effect of CD4-blockade
did not interfere with overall immune competence, as anti-CD4 treated mice remained
fully competent to respond to unrelated antigens. Protection from anaphylaxis correlated
with increased frequency of Foxp3+ regulatory T cells (Treg), and was abrogated fol-
lowing Treg depletion. Taken together our data suggest that activation of T cells by CPE
in presence of CD4-blockade leads to Treg expansion that can prevent peanut-induced
anaphylaxis.
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INTRODUCTION
Anaphylaxis is an acute, life-threatening, allergic reaction where
a physiologic process that normally acts in a local and limited
manner to protect against infection occurs massively and systemi-
cally. Peanut allergy is a major cause of food-induced anaphylaxis,
affecting around 1% of the population, with increasing prevalence
worldwide (Kanny et al., 2001; Sampson, 2004). To date there is
no cure for peanut allergy, and unlike many other food allergies, it
persists through adulthood. Currently, avoidance is the only treat-
ment advised. There is therefore, a clear need for safe and effective
tolerance-inducing therapies for patients who might be exposed
to anaphylactic reactions.
Monoclonal antibodies (mAb) that target T cell co-receptor and
co-stimulatory molecules have been reported effective in induc-
ing tolerance to non-self antigens.Waldmann and coworkers have
shown non-lytic CD4 antibodies (with an isotype that does not
directly deplete target cells) can induce long-term transplanta-
tion tolerance in mice (Graca et al., 2003; Kendal and Waldmann,
2010). The resulting tolerance state is mediated by Foxp3+ regu-
latory T cells (Treg), although other mechanisms may also operate
(Graca et al., 2002, 2004; Lin et al., 2002). It was reported that
a non-depleting anti-CD4 mAb was effective in preventing aller-
gic airways disease in mice sensitized with ovalbumin (OVA; Li
et al., 1999a). We have recently extended these data, showing that
tolerance can be induced in mice to a clinically relevant aeroal-
lergen – house dust mite (HDM). In this case, tolerant mice were
protected from airways hyperreactivity (AHR), eosinophilia, gob-
let cell hyperplasia, and production of antigen-speciﬁc IgG1 and
Abbreviations: AHR, airway hyperreactivity; Alum, aluminum hydroxide; CPE,
crudepeanut extract;HDM,housedustmite; i.p., intra peritoneal;mAb,monoclonal
antibody; OVA, ovalbumin.
IgE (Agua-Doce and Graca, 2011). These data contrasts with the
disappointing results from a clinical trial with a depleting anti-
CD4 mAb (keliximab; Kon et al., 1998). In this trial the depleting
nature of the mAb precluded the use of a dose sufﬁcient to achieve
effective CD4-blockade, as it led to immune suppression.
Surprisingly, the same non-depleting anti-CD4 mAb we suc-
cessfully used to induce tolerance to HDM (or OVA) was reported
to be less effective when tolerance was induced to systemically
delivered human factor VIII in a mouse model of hemophilia
(Salooja et al., 2002). Therefore, we decided to explore to which
extentCD4-blockade is able toprevent a systemic allergic response:
anaphylaxis.
We took advantage of a well established model of peanut-
induced anaphylaxis, where the antigen crude peanut extract
(CPE) is delivered through i.p. injection, allowing the precise con-
trol of the dose and time of exposure (Pons et al., 2004). C3H/HeJ
micehavehigh susceptibility topeanut-induced anaphylaxis,being
able to produce high peanut-speciﬁc antibody titers. Moreover,
upon challenge through the i.p. route, these mice develop mani-
festations of anaphylactic shock, including a sharp drop of body
temperature, which facilitates the quantiﬁcation of clinical mani-
festations, and resemble anaphylactic reactions in human subjects
(Li et al., 2000; Berin et al., 2006).
We conﬁrmed C3H/HeJ mice can be sensitized with CPE,
producing high titers of CPE-speciﬁc Th2-driven antibodies. We
found that CD4-blockade, during the sensitization, prevented the
generation of peanut-speciﬁc immunoglobulins, even following
subsequent sensitization with CPE-alum, rendering the mice pro-
tected from anaphylaxis. The protective effect is abrogated follow-
ing depletion of Treg cells. Importantly, CD4-blockade does not
lead to immune deﬁciency, as mice remain competent to respond
to different antigens.
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MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
C3H/HeJmicewere bred andmaintainedunder speciﬁc pathogen-
free facilities.Animalswere sex-matched andused at 6–10weeks of
age. All experiments involving animals were approved by Direccao
GeralVeterinaria (approval 018831). Sensitizationwas achieved by
administration of 0.5mgCPE in 2mg aluminumhydroxide (alum,
Alu-gel-S, Serva, Heidelberg, Germany) i.p. at days 1, 7, and 21.
Mice were subsequently challenged with 10mg CPE in PBS i.p.
CLINICAL ASSESSMENT OF ANAPHYLAXIS
Mice were assessed during 45min following CPE challenge. Body
temperature was measured at the indicated times with a rec-
tally inserted thermal probe. The clinical score was evaluated
as described elsewhere (Li et al., 2000): 0 – no manifestations;
1 – Scratching/rubbing around the nose and head; 2 – pufﬁness
around eyes and mouth, reduced activity, diarrhea, pilar erecti;
3 – wheezing, labored respiration, cyanosis aroundmouth and tail;
4 – no activity after prodding, or tremor and convulsion; 5 – death.
Scoring was performed blinded by two independent researchers.
CPE PREPARATION
Peanut ﬂour was extensive defatted with diethyl ether, and the
dried defatted peanut ﬂour was extracted in ice-cold 10× PBS
overnight at 4˚C, centrifuged at 30,000 g for 60′, and ﬁlter-
sterilized. Protein concentration was measured with the BCA
method and aliquots were stored at −20ºC.
MONOCLONAL ANTIBODIES
Non-depleting anti-CD4 (YTS177), the isotype control (YKIX302),
and anti-CD25 (PC61) mAbs were produced in our laboratory
using Integra CL1000 ﬂasks (IBS, Chur, Switzerland), puriﬁed by
50% ammonium sulfate precipitation, dialyzed against PBS, and
purity checkedbynative and SDSgel electrophoresis. The hybrido-
mas were generously provided by Professor Herman Waldmann
(Oxford, UK).
IN VITRO CULTURES
Splenocytes (1× 106) were cultured for 3 days in 96 well plates,
with complete culture medium (RPMI-1640 with Glutamax, sup-
plemented with 10% FBS, 1% hepes, 1% penicillin/streptomycin,
1% sodium pyruvate, 0.1% β-mercaptoethanol; Invitrogen), with
addition of 20μg OVA or CPE. At day 3, cells were centrifuged
and supernatants recovered and kept at −80º C until cytokine
quantiﬁcation.
ELISA
The serum IgE and CPE- or OVA-speciﬁc IgG1 was measured
in microtiter plates coated with 50μg/ml CPE or OVA. IgE was
quantiﬁed with an Opteia kit (BD Pharmingen) and IgG1 with
a kit from Southern Biotech. Quantiﬁcation of cytokines in cell-
culture supernatants was performed using IL-10 and IL-13 kits
(Peprotech, London, UK), and IL-5 Opteia kits (BD Pharmin-
gen). All assays were performed according to the manufacturer’s
instructions.
FLOW CYTOMETRY
Single cell suspensions were analyzed with the following
ﬂuorochrome-labeled mAb: CD3 Percp–Cy5.5 (145–2C11), CD4
PE (GK1.5),CD8APC–Cy7 (53–6.7),CD25 Pe–Cy7 (PC61.5), and
Foxp3 (FJK165; eBiosciences). Samples were run in a FACS Canto
and analyzed with FlowJo.
STATISTICAL ANALYSIS
Statistical signiﬁcance was determined using the two-tailed non-
parametric Mann–Whitney U test and P values< 0.05 were
deemed signiﬁcant (∗P < 0.05; ∗∗ P < 0.01; ∗ ∗ ∗ P < 0.001).
RESULTS
CPE-INDUCED AN ANAPHYLACTIC RESPONSE IN SENSITIZED C3H/HEJ
MICE
C3H/HeJ mice have been widely used as an experimental murine
model of allergic diseases, being prone for the development of
Th2-like immune responses, namely peanut-induced anaphylaxis
(Li et al., 2000;Morafo et al., 2003).We found that upon i.p. sensi-
tization with CPE-alum, an anaphylactic response was observed
following challenge with CPE administered i.p. (Figure 1A).
Female mice appeared to display greater disease severity, how-
ever, both males and females developed clinical manifestations
of anaphylaxis, reaching a state where they did not respond to
external stimuli (score 4). In addition, these mice displayed a
sharp drop in body temperature, during the initial 45′ following
challenge with CPE (Figures 1B,C). Serum concentration of Th2-
driven immunoglobulins, such as IgE and CPE-speciﬁc IgG1,were
markedly increased in CPE-sensitized mice, compared to non-
exposed controls (Figures 1D,E). These data are similar to prior
reports (Li et al., 2000; Pons et al., 2004), supporting the use of
C3H/HeJ mice as an adequate model for the study of anaphylaxis.
NON-DEPLETING ANTI-CD4 mAb PREVENTED CPE-INDUCED
ANAPHYLAXIS
We have recently shown non-depleting anti-CD4 mAb can pre-
vent allergic airways disease in mice in an antigen-speciﬁc way
(Agua-Doce and Graca, 2011). To assess if this monoclonal anti-
body was equally efﬁcient in the prevention of a systemic Th2-
driven response, we investigated whether anti-CD4 treatment
could prevent anaphylaxis in C3H/HeJ mice.
We found anti-CD4 treatment at the time of sensitization was
effective in preventing the development of anaphylactic mani-
festations observed during the 45min following challenge with
CPE (Figures 2A,B). Anti-CD4 treated mice also maintained their
body temperature, unlike control animals where the temperature
dropped rapidly (Figure 2C). The production of IgE and CPE-
speciﬁc IgG1 was also impaired in mice treated with anti-CD4
(Figures 2D,E).
ANTI-CD4 DID NOT PREVENT ANAPHYLAXIS IN PRE-SENSITIZED MICE
WITH HIGH IGE
We next assessed the impact of anti-CD4 treatment in pre-
sensitized mice. Note that the exposure to CPE at days 36–58
(Figure 3A), probably due to the use of alum, only induced mild
clinical manifestations of disease even in the absence of anti-CD4
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FIGURE 1 | Crude peanut extract induces anaphylaxis in C3H/HeJ mice.
(A) C3H/HeJ mice were sensitized i.p. with 0.5mg CPE in 2mg alum on days
1, 7, and 21. The animals were assessed at day 36 following challenge with
10mg CPE i.p., with clinical score and temperature monitored during 45min
after challenge. (B) Clinical score was evaluated as described in the Section
“Materials and Methods,” and (C) body temperature was measured. Females
show more severe clinical manifestations of anaphylaxis, compared to male
mice, but without reaching statistical signiﬁcance. (D)Total IgE and (E)
CPE-speciﬁc IgG1 were measured in the serum of individual mice. Both
males and females showed an increase in the immunoglobulin levels
compared to naïve mice (n =5, ** P <0.01). Data (B–E) are representative of
two independent experiments.
(not shown). Furthermore, in spite of such mild clinical mani-
festations of anaphylaxis, all mice strongly developed anaphylaxis
when exposed to CPE without alum at day 73 (Figures 3B,C).
We found that mice sensitized with CPE in advance of anti-
CD4 treatment were not protected from the development of
clinical manifestations of anaphylaxis, namely reduction of body
temperature (Figures 3B,C). Mice treated with anti-CD4 had
increased levels of total IgE and CPE-speciﬁc IgG1, similar to
CPE-sensitized controls (Figures 3D,E). These results suggest that
in pre-sensitized individuals pre-existing IgE, produced at the
time of initial sensitization, will drive clinical manifestations of
anaphylaxis in a T-cell independent manner.
NON-DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY-INDUCED
PROTECTION FROM SUBSEQUENT EXPOSURE TO CPE
Non-depleting anti-CD4mAbwas shown to induce long-term tol-
erance in transplantation (WaldmannandCobbold,2001).Wealso
found long-term protection to HDM could be induced with this
mAb in mice (Agua-Doce and Graca, 2011). Therefore, we evalu-
ated whether treatment with non-depleting anti-CD4 at the time
of CPE sensitization could protectmice frompeanut-induced ana-
phylaxis following a subsequent sensitization. As a consequence,
2 weeks after treatment,mice were re-sensitized with CPE-alum as
shown in Figure 4A. The 2weeks is sufﬁcient to allow for clearance
of the mAb below therapeutic levels, as we found by treating mice
with anti-CD4 2weeks in advance of providing the antigen (in
previous experiments using OVA as the antigen, data not shown).
Manifestations of anaphylaxis were evident after challenge in
CPE-sensitized mice, whereas mice treated with anti-CD4 were
protected from severe clinicalmanifestations (Figure 4B). In addi-
tion, serum titers of IgE and CPE-speciﬁc IgG1 remained low
in mice treated with anti-CD4 (Figure 4C). Injection of alum
alone (in the absence of antigen and anti-CD4) did not prevent
subsequent response elicited following sensitization (not shown).
We next compared the production of Th2-type cytokines by T
cells from anti-CD4 treated mice. We cultured spleen T cells for
3 days in presence of CPE stimulation,andquantiﬁed the cytokines
in cultures supernatants. T cells from mice treated with anti-
CD4 mAb, unlike splenocytes from control CPE-sensitized mice,
did not produce detectable levels of IL-5 and IL-13 (Figure 4D).
Several reports have implicated IL-10 in protection from allergy
(Akdis et al., 1998, 2004). However, production of IL-10 follow-
ing in vitro stimulation with CPE was also reduced in cells from
anti-CD4 treated mice (Figure 4D). In fact, IL-10 production was
higher in cells from animals sensitized with CPE in the absence of
anti-CD4 treatment.
Several studies in transplantation have shown that long-term
tolerance induced with CD4-blockade is associated with Foxp3+
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FIGURE 2 | Anti-CD4 prevents peanut-induced anaphylaxis in C3H/HeJ
mice. (A) Female C3H/HeJ mice were sensitized to CPE at the indicated
days, with a group of animals being treated with 1mg anti-CD4 or an isotype
control i.p. at the time of each sensitization. All mice were assessed at day 36
following challenge with 10mg CPE i.p. (B) Mice were assessed for their
clinical score and (C) body temperature during 45min following CPE
challenge. Anti-CD4 treated mice did not develop any signiﬁcant
manifestations of disease (n =4, * P <0.05). In addition, CPE-sensitized mice
showed a sharp drop of body temperature (n =4, * P <0.05). (D) Serum
concentration of total IgE and (E) CPE-speciﬁc IgG1. Anti-CD4 treated mice
maintained IgE levels at a concentration similar to naïve non-immunized mice,
while mice treated with an isotype control signiﬁcantly increased serum IgE
and IgG1 (n =8, *** P <0.001). Data (B–E) are representative of three
independent experiments.
Treg expansion (Cobbold et al., 2004; Graca et al., 2005; Oliveira
et al., 2011). We found that although the anti-CD4 mAb has a
non-depleting isotype, and does not directly lyse CD4+ T cells
(Figure A1 in Appendix), the absolute number of CD4+ T cells in
the spleen of anti-CD4 treated mice were lower than in controls
(Figure 4E). However, the frequency of Foxp3+ Treg cells within
the T cell population was signiﬁcantly increased in anti-CD4
treated mice (Figure 4E).
To further conﬁrm the participation of Treg cells in the
protection induced following anti-CD4 treatment, we evalu-
ated the efﬁcacy of CD4-blockade in CD25-depleted mice. We
found that mice depleted of CD25 T cells at the time of CD4-
blockade were not protected from peanut-induced anaphylaxis,
induced following subsequent immunization with CPE-alum as
described in Figure 4A. In fact, CD25-depleted mice exhib-
ited high levels of total IgE, similar to what was observed in
mice not treated with anti-CD4 (Figure 4F). These data sug-
gest Foxp3+ Treg cells participate in protection from peanut-
induced anaphylaxis induced following CD4-blockade. In addi-
tion, we compared the effect of CD25 depletion when applied
before or after tolerance induction with anti-CD4. We found
that treatment with anti-CD25 in advance of tolerance induc-
tion was not as effective in abrogating tolerance induction as
when CD25 depletion was performed after anti-CD4 treatment
(Figure 4G). These data suggest the participation of adaptive Treg
cells, induced at the time of anti-CD4 treatment, in tolerance
induction.
ANTI-CD4 TREATMENT INDUCED ANTIGEN-SPECIFIC PROTECTION
We ﬁnally assessed whether anti-CD4 treatment was affecting the
global immunocompetence,by studying the ability ofmAb-treated
mice to respond to different antigens. Therefore, following treat-
ment of C3H/HeJ mice with CPE in presence of anti-CD4, some
mice were re-sensitized with the same (CPE) or a different (OVA)
antigen (Figure 5A). Mice treated with anti-CD4 remained fully
competent to respond to sensitization withOVA-alum,developing
a Th2-immune response leading to production of high IgE titers
(Figure 5B). In fact, the levels of IgE were comparable to what was
observed in CPE-sensitized control mice.
Conversely, when we treated mice with anti-CD4 together
with OVA, we prevented production of IgE following subsequent
sensitization with OVA (Figure 5C).
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FIGURE 3 | Anti-CD4 does not prevent anaphylaxis in
pre-sensitized mice with high titers of IgE. (A) C3H/HeJ mice
were sensitized with CPE-alum on days 1, 7, and 21, and treated with
anti-CD4 administered together with CPE at the indicated days. All mice
were assessed at day 73 after challenge with 10mg CPE i.p.
(B) Sensitized mice subsequently treated with anti-CD4 (CPE> tCPE)
displayed anaphylactic manifestations identical to the control group, as
well as (C) sharp reduction of body temperature. (D)Total IgE and
(E) CPE-speciﬁc IgG1 levels were similar in sensitized mice even when
treated with anti-CD4 after sensitization (CPE and CPE> tCPE). These high
levels of immunoglobulins contrast with mice treated with anti-CD4 at the
time of initial sensitization (tCPE) that maintain low titers of IgE and IgG1
(n =4, *** P <0.001). Data (B–E) are representative of two independent
experiments.
Taken together these data show anti-CD4 treatment induces
unresponsiveness to the antigens administered at the time of
CD4-blockade,without preventing subsequent immune responses
to different antigens. Therefore, anti-CD4 treated mice remain
immune competent.
DISCUSSION
Our data show CD4-blockade is effective in inducing antigen-
speciﬁc tolerance toCPE, thus preventing subsequent sensitization
with the same antigens. This conclusion contrasts with the appar-
ent difﬁculty to induce tolerance in mice to systemically delivered
human factor VIII or factor IX using the same mAb (Salooja et al.,
2002). We are currently investigating the mechanisms that may
explain the reason distinct proteins are tolerated with different
ability.
Anti-CD4 is a non-depleting monoclonal antibody which has
been extensively studied in several animal models of immune
pathology. In transplantation and autoimmune arthritis, non-
depleting anti-CD4 is effective in preventing transplant rejection
and inducing long-term tolerance in mice (Waldmann and Cob-
bold, 2001; Duarte et al., 2010). Experiments with TCR-transgenic
mice have shown the tolerant state is maintained by Foxp3+
Treg cells that can be induced from Foxp3− precursors (Cob-
bold et al., 2004; Oliveira et al., 2011). Such T cells can actively
maintain tolerance by recruiting non-tolerant cells into the reg-
ulatory pool – a phenomenon termed infectious tolerance (Qin
et al., 1993; Graca et al., 2000; Waldmann et al., 2006). In fact,
mice transplanted under the cover of non-depleting anti-CD4
mAb do not become tolerant (i.e., they reject the transplant)
when treated with anti-CD25 (Cobbold et al., 2006). We fol-
lowed the same approach to show mice treated with anti-CD25
remained competent to produce CPE-speciﬁc antibodies, sug-
gesting a similar mechanism of action. We cannot exclude that
part of the effect of CD4-blockade is due to activation-induced
cell death of T cells speciﬁc for the antigen present at the time
of tolerance induction – a mechanism well described in trans-
plantation tolerance induced with co-stimulation blockade (Li
et al., 1999b; Wells et al., 1999). In any case, Treg cells appear
to play the key role in our experiments, something suggested not
only by the Treg-depletion experiment, but also by the marked
increase in the frequency of Foxp3+ T cells in anti-CD4 treated
mice. In addition we found that Treg depletion in advance of
anti-CD4 treatment did not have a major impact on tolerance
induction. On the contrary, CD25 depletion after anti-CD4 treat-
ment abrogated tolerance induction. Although these data are not
conclusive, as we cannot follow the fate of antigen-speciﬁc cells,
they suggest that induced Treg cells are probably key participants
in tolerance induction. Such tolerance mechanism is also distinct
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FIGURE 4 | Anti-CD4 treated mice are protected from subsequent
sensitization with CPE. (A) C3H/HeJ mice were treated with
anti-CD4 (tCPE) at the time of initial sensitization. Following 2weeks, the
mice were sensitized with CPE-alum (tCPE>CPE) and ﬁnally
assessed at day 73 following challenge with 10mg CPE i.p. (B) Mice treated
with anti-CD4 (tCPE), even when re-sensitized with CPE-alum (tCPE>CPE),
did not develop anaphylactic manifestations as severe as CPE-sensitized
group (CPE), showing clinical scores and body temperature signiﬁcantly
different (n =5, * P <0.05). (C) All groups of mice treated with anti-CD4,
showed no signiﬁcant increase in IgE and CPE-speciﬁc IgG1 levels when
compared to naïve mice. TheTh2-driven immunoglobulins were signiﬁcantly
increased in CPE-sensitized mice (n =5, * P <0.05, ** P <0.001,
*** P <0.001). (D) Cytokines were measured in the supernatants of
CPE-stimulated spleen cells. IL-5, IL-13, and IL-10 were almost undetectable in
anti-CD4 treated mice following re-sensitization (tCPE>CPE) and signiﬁcantly
reduced compared with untreated mice (n =5, * P <0.05). (E)The number of
splenic CD4+ T cells was reduced in anti-CD4 treated mice, while the
frequency of CD4+Foxp3+ T cells was signiﬁcantly higher (n =5, * P <0.05).
(F) C3H/HeJ mice were treated as described above, while some animals
were depleted of CD25 cells at the time of anti-CD4 treatment
(tCPE+ aCD25>CPE). CD25 depletion abrogated protection, leading to
production of IgE to levels similar to mice not treated with anti-CD4. (G)We
compared the effect of CD25 depletion before and after treatment with
anti-CD4 (2×1mg, 10 and 8 days before, or after tolerance induction with
CPE+ anti-CD4). Control mice were CD25-depleted before challenge with
CPE, in the absence of treatment with anti-CD4 (n =5, * P <0.05,
** P <0.001, *** P <0.001). Data (B–F) are representative of two
independent experiments.
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FIGURE 5 | Anti-CD4 treatment induces antigen-specific tolerance. (A)
C3H/HeJ mice were sensitized with CPE or OVA, and treated with anti-CD4
as described. The animals were assessed at day 73. (B) Mice treated with
anti-CD4 mAb (tCPE) even following subsequent sensitization with the same
antigens (tCPE>CPE) maintained IgE titers signiﬁcantly lower than control
animals (CPE; *P <0.05). However, anti-CD4 treatment did not prevent the
production of IgE following subsequent sensitization with OVA, a different
antigen (tCPE>OVA), that led to IgE titers similar to the levels of control mice
(CPE). (C) Equivalent experiment to (B) where OVA was used as the antigen
to sensitize C3H/HeJ mice. OVA sensitization led to high titers of IgE (OVA).
Exposure to OVA in presence of CD4-blockade (tOVA) prevented IgE
production even following subsequent sensitization with OVA (tOVA>OVA)
(n =5, * P <0.05). Data (B,C) are representative of two independent
experiments.
from other immune tolerance induction protocols that rely on the
production of IL-10 or shifting the response toward Th1 (Ebner
et al., 1997; Francis et al., 2003; Akdis et al., 2004; Valenta et al.,
2004).
When we treated with anti-CD4 mAb mice previously sensi-
tized with CPE, we could not prevent manifestations of anaphy-
laxis given the presence of high IgE titers. It remains, however, to
be shown whether therapeutic neutralization of IgE, could allow
tolerance to be imposed in a way preventing further production
of IgE. In fact, our results with a mouse model of allergic airways
disease show that tolerance can be achieved in pre-sensitized mice,
even following one episode of airways inﬂammation (Agua-Doce
and Graca, 2011). Taken together, these ﬁndings suggest IgE is
not preventing tolerance from being achieved within the T cell
compartment, but high levels of IgE are sufﬁcient to lead to acute
manifestations of disease. In addition, memory cells have been
recognized as a major barrier for therapeutic induction of toler-
ance (Adams et al., 2003). In any case, immune tolerance can be
induced in some experimental models with anti-CD4, in presence
of memory T cells (Agua-Doce and Graca, 2011). Concerning tol-
erance induction to CPE, we cannot conclude whether, besides
high IgE levels, the presence of memory T cells in pre-sensitized
mice constitute a barrier to tolerance induction.
Interestingly, we found sensitized mice only developed mild
manifestations of anaphylaxis when injected with CPE-alum,
while CPE alone triggered a severe anaphylactic response with
a sharp drop in core body temperature. However, when we
injected alum alone, or alum together with a different antigen
(OVA),we could not observe a protective effect toward subsequent
sensitization with CPE.
To ﬁnd an efﬁcient and speciﬁc therapy for peanut-induced
anaphylaxis has been a major challenge (Burks et al., 2008). Once
the diagnosis is established, the course of action is restricted to
strict elimination of the causative allergen from the patient’s diet,
and it was estimated that about 50% of the affected individu-
als develop an accidental reaction over a 2-year period (Sicherer
et al., 2003). Distinct approaches to induce tolerance to food aller-
gens have been or are being pursued (Canonica and Passalacqua,
2003; Clark et al., 2009; Jones et al., 2009; Blumchen et al., 2010;
Vickery et al., 2011). It is however yet unclear whether the evi-
dence will support clinical adoption of any of those tolerogenic
strategies.
We believe our data provide evidence that targeting CD4 T cells
may provide a way to achieve or facilitate tolerance induction to
systemic antigens, such as the ones that may trigger anaphylaxis.
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APPENDIX
FIGUREA1 | Anti-CD4 treatment does not directly depleteT cells in the
absence of antigen. DO11.10.Rag−/− mice were treated with two shots of
1mg anti-CD4 in alternate days. Spleen and LN were collected at day 7 and
stained with theTCR-speciﬁc mAb (KJ1-26) and Foxp3. No signiﬁcant
difference was observed in the frequency or number of T cells from
mAb-treated animals.
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